Effect of cerebrolysin in patients with ischemic stroke: A double-blind randomized control study
Abstract
We investigated the effect of cerebrolysin compared with placebo efficacy in patients with ischemic stroke. A total of 50 patients with ischemic stroke participate in this randomized double-blind placebo-controlled study. Patients were randomly divided into two groups; main group (n=25) was treated by 30cc IV cerebrolysin daily for 5 days. Control group (n=25) administrated 30 cc IV normal saline as a placebo daily during first five days of stroke attack. Three scoring system was used in the present study: National Institutes of Health Stroke Scale (NIHSS) on admission and after five days, and Barthel and Rankin’s scale after the 90 days. Data were analyzed by SPSS 16 using t-test. P-value less than 0.05 considered as significant level. The NIHSS score showed no significantly difference after 5 days (independent t-test, P = 0.195). There was a significant difference between Barthel and Rankin’s scale after 90 days (P = 0.039 and P = 0.008 respectively). In conclusion, cerebrolysin prevented the development of ischemic stroke’s sign and symptoms through 90 days.
Keywords
Full Text:
PDFReferences
Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 57:1595-1602, 2001.
De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. Dec 22:535-540, 1999.
Martinez-Vila E, Sieira PI. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 11:60-70, 2001.
Sacco RL, DeRosa JT, Haley EC, Jr., et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285:1719-1728, 2001.
Bath PM, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev 2:CD005207, 2007.
Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33:2123-2136, 2002.
Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 3:CD001244, 2003.
Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 61:396-402, 2007.
Ladurner G, Kalvach P, Moessler H. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm 112:415-428, 2005.
Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 28:307-310, 1997.
Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J. Feb 1965;14:61-65.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607, 1988.
Lin SZ, Hoffer BJ, Kaplan P, Wang Y. Osteogenic protein-1 protects against cerebral infarction induced by MCA ligation in adult rats. Stroke 30:126-133, 1999.
Schabitz WR, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17:500-506, 1997.
Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 354:588-600, 2006.
Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357:562-571, 2007.
Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39:1751-1758, 2008.
Kawamata T, Dietrich WD, Schallert T, et al. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci U S A 94:8179-8184, 1997.
Refbacks
- There are currently no refbacks.